Business Context and Reporting Period
This Form 8-K Current Report, dated November 1, 2021, details a material transaction by iBio, Inc. (the "Company") and its subsidiary, iBio CDMO LLC. The Company acquired its 130,000 square-foot cGMP manufacturing facility in Bryan, Texas, along with the associated ground lease rights and the remaining equity interest held by its former landlord/affiliate, Bryan Capital Investors LLC. This transaction consolidates the Company's ownership of its primary production asset and terminates the previous sublease arrangement.
Key Financial Metrics and Transaction Details
- Total Purchase Price: $28,750,000 for the facility, ground lease rights, and equity interest.
- Payment Structure: $28,000,000 paid in cash and the issuance of a warrant to purchase 1,289,581 shares of common stock at an exercise price of $1.33 per share.
- Debt Financing: The Company secured a $22,375,000 secured term loan from Woodforest National Bank to fund a portion of the purchase price.
- Loan Terms: Interest rate of 3.25% payable monthly; principal due November 1, 2023.
- Lease Obligations: The Company assumed a ground lease with Texas A&M University System until 2060. Base rent is 6.5% of Fair Market Value (previously $151,450 for the prior year).
- Liquidity Covenant: The Credit Agreement requires the Company to maintain unrestricted cash of no less than $10,000,000.
Material Changes Versus Prior Period
The filing represents a significant structural change in the Company's asset base and capital structure:
- Asset Ownership: Transitioned from a subtenant to the direct owner of the facility and tenant under the ground lease.
- Equity Structure: iBio CDMO is now a wholly-owned subsidiary following the acquisition of the 0.01% interest previously held by Bryan Capital.
- Debt Load: Incurred a new $22,375,000 term loan obligation, secured by a first lien on all assets of iBio CDMO and a leasehold deed of trust on the facility.
- Agreement Termination: Terminated the Sublease Agreement dated January 13, 2016, and all other agreements between the Company and the Seller.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The transaction secures the Company's long-term operational footprint through 2060 and removes the previous sublease dependency. The warrant issued to the Seller is exercisable immediately and expires on October 10, 2026, with provisions for cashless exercise.
Risks and Covenants:
- Default Risks: The Credit Agreement includes standard events of default, including nonpayment, breach of covenants, and cross-defaults.
- Restrictive Covenants: The Company is prohibited from incurring additional debt (except permitted debt) or liens without lender consent and must maintain the $10,000,000 unrestricted cash balance.
- Collateral: The loan is fully secured by the facility, a letter of credit from JPMorgan Chase Bank, and a first lien on all iBio CDMO assets.
Key Facts for Investor Verification
- Verify the Company's current unrestricted cash balance to ensure compliance with the $10,000,000 covenant requirement.
- Confirm the impact of the new $22,375,000 debt service (3.25% interest) on future cash flow projections.
- Review the valuation and dilution impact of the warrant issued for 1,289,581 shares at $1.33 per share.
- Assess the terms of the ground lease with Texas A&M University System, specifically the mechanism for calculating the 6.5% Fair Market Value rent.
- Examine the "Permitted Debt" definitions in the Credit Agreement to understand future financing flexibility.